Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease
Article first published online: 22 MAR 2001
Copyright © 2001 Wiley-Liss, Inc.
American Journal of Hematology
Volume 66, Issue 4, pages 292–294, April 2001
How to Cite
Friederich, P. W., Wever, P. C., Briët, E., Doorenbos, C. J. and Levi, M. (2001), Successful treatment with recombinant factor VIIa of therapy-resistant severe bleeding in a patient with acquired von Willebrand disease. Am. J. Hematol., 66: 292–294. doi: 10.1002/ajh.1060
- Issue published online: 22 MAR 2001
- Article first published online: 22 MAR 2001
- Manuscript Accepted: 4 OCT 2000
- Manuscript Received: 10 MAR 2000
- acquired von Willebrand disease;
- recombinant factor VIIa;
We describe an elderly man who presented with life-threatening hematuria and gastrointestinal bleeding caused by acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance (MGUS). Standard therapy with desmopressin, von Willebrand factor-containing factor VIII concentrate, tranexamic acid, and immunoglobulin failed to achieve adequate hemostasis. However, treatment with recombinant activated factor VII (rFVIIa) arrested the bleeding completely. Since acquired von Willebrand disease can lead to life-threatening hemorrhage, clinicians should consider rFVIIa as an effective treatment option if standard therapy fails. Am. J. Hematol. 66:292–294, 2001. © 2001 Wiley-Liss, Inc.